Ohki et al33 reported a significant reduction in serum ALT levels following treatment with SGLT2 inhibitors in Japanese, type 2 diabetic patients with non-alcoholic fatty liver disease. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.